Celmatix
Celmatix is a women's health biotech company pioneering ovarian health therapeutics that translate advances in female biology into novel drug candidates. The company's discovery portfolio, recently acquired by Gedeon Richter, includes a first-in-class oral FSH receptor agonist with the potential to transform fertility care through patient-friendly ovarian stimulation, a novel JNK inhibitor representing a…
Funding snapshot
About
Celmatix is a women's health biotech company pioneering ovarian health therapeutics that translate advances in female biology into novel drug candidates. The company's discovery portfolio, recently acquired by Gedeon Richter, includes a first-in-class oral FSH receptor agonist with the potential to transform fertility care through patient-friendly ovarian stimulation, a novel JNK inhibitor representing a non-hormonal immunotherapy approach for endometriosis targeting pain and inflammation, and early-stage AMH-targeting antibodies designed to expand control over ovarian folliculogenesis. Celmatix also received a $3.5M award from ARPA-H's Sprint for Women's Health and has nominated lead compounds in its oral fertility drug program. The company leverages DNA-Encoded Chemistry Technology (DEC-Tec) platforms in partnership with Baylor College of Medicine. Founded in 2009 and headquartered in New York City, Celmatix has raised approximately $24.9M in Series C funding from investors including Topspin Consumer Partners, Partnership for New York City, and Lauder Partners.
Business model
Women Health > In Vitro Diagnostic Tests > Fertility > Pregnancy,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Single Gene Tests or Panels
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.